LENZ

LENZ is a one-product commercial-stage biotech whose entire thesis rides on VIZZ (aceclidine 1.44%), the first and only FDA-approved aceclidine eye drop for presbyopia, launched in the U.S. in August 2025. The numbers look ugly on the surface — FY2025 net loss of $82.1M on just $19.1M of (partial first-year) revenue, an operating margin of -477.5%, and operating cash flow of -$69.2M — but this is exactly what an early drug launch burns. The more important fact the market seems to be discounting is the balance sheet: management reports $292.3M of cash, restricted cash and marketable securities against only $21.5M of total liabilities, versus a market cap of just $185M. In other words, the stock trades below its net cash. You are effectively being handed the VIZZ franchise — patent-protected in the U.S. to 2044 with NCE exclusivity to July 2030, addressing an estimated $3B+ U.S. market and 128M presbyopes — for less than the cash in the bank.

That is the crux of the buy case: a hard valuation floor plus a real, differentiated, IP-protected asset with meaningful optionality. Management explicitly states existing liquidity is expected to fund the company to positive operating cash flow, which — if credible — removes the usual 'will they run out of money' overhang that sinks pre-profit biotech. Stockholders' equity of $284M against a $185M cap and liabilities/equity of just 0.08x means there is no balance-sheet stress here; the risk is entirely commercial, not financial.